ONCOMATRYX Secures $67 Million to Advance Clinical Development of Quantum ADCs. The funding, led by several investors including a strategic investment from the Spanish Government, aims to propel clinical trials for its novel therapies.
Amount Raised
$67 Million
Round Type
Corporate Round
Autonomous Community Of The Basque CountryBiotechnologyHealth CareTherapeuticsInvestors
Description
ONCOMATRYX, a Spanish biopharmaceutical company, raised $67 million for the development of its Quantum ADCs. The funding round was led by institutional investors, including $28 million from the Spanish Government. This support will facilitate clinical trials for their leading candidates, including OMTX705. The investment underscores confidence in innovative oncology therapies.
Quick answer
Oncomatryx Biopharma raised $67 Million in a Corporate Round round, dated March 30, 2026. Investors: Bbk, Ekarpen VC, Basque Government, Kutxa Fundazioa and Spanish Government. Oncomatryx Biopharma is based in Autonomous Community Of The Basque Country, Spain.
- How much did Oncomatryx Biopharma raise?
- Oncomatryx Biopharma raised $67 Million in a Corporate Round round on March 30, 2026.
- Who invested in Oncomatryx Biopharma?
- Bbk, Ekarpen VC, Basque Government, Kutxa Fundazioa and Spanish Government are named as investors in this round.
- What does Oncomatryx Biopharma do?
- Oncomatryx Biopharma is a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology.
- Where is Oncomatryx Biopharma based and how big is it?
- Oncomatryx Biopharma is based in Autonomous Community Of The Basque Country, Spain.
- Who are the decision-makers at Oncomatryx Biopharma?
- Fundz holds 2 contacts at Oncomatryx Biopharma, including the Director of Manufacturing. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Oncomatryx Biopharma that raised within 45 days of this round, from Fundz verified event records.
- CREATE Medicines raised $122M (Series B) on May 14, 2026.
- Ollin Biosciences raised $330M (Series B) on May 14, 2026.
- Remedium Bio raised $10M (Series A) on May 6, 2026.
- Citius Oncology raised $37M on May 6, 2026.
- Windward Bio raised $165M (Funding Round) on May 5, 2026.
- Aura Biosciences, Inc. raised $238M (Post-IPO Equity) on May 4, 2026.
Who to call at Oncomatryx Biopharma, and when
A new round usually means Oncomatryx Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Oncomatryx Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Oncomatryx Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Oncomatryx Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Oncomatryx Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Oncomatryx Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.